Alignment Healthcare, Inc. (ALHC): who owns it and who trades it
As of Nov 16, 2026, ALHC insiders reported 77 open-market sales worth $311M and 1 purchase worth $198K in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was General Atlantic (ALN HLTH), L.P. (10% owner), with $206M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Alignment Healthcare
From the latest filingsOverall: more selling than buying. Funds and insiders mostly sold. Famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ALHC
2 funds and institutions reported ALHC shares worth $20.4B at the end of Q2 2026, about 6% of the company. The largest holder is Picton Mahoney Asset Management with 5.8%.
Funds and institutions (13F) 6%Everyone else 94%
10 largest owners, by share of the company
Top 2 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Picton Mahoney Asset Management | 12.00M | 5.80% | $20.4B | +140% |
| Boussard & Gavaudan Gestion Sas | 5,000 | 0.00% | $8.6M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ALHC insiders reported $198K of open-market purchases and $311M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Joseph S Konowiecki | Vice president | Sale | 4,930 | $7.20 | $35.5K | Form 4 |
| Oct 6, 2026 | Hyong Kim | Chief Medical Officer | Sale | 32,479 | $8.30 | $270K | Form 4 |
| Sep 17, 2026 | Joseph S Konowiecki | Vice president | Sale | 23,511 | $8.61 | $202K | Form 4 |
| Sep 14, 2026 | John E Kao | CEO | Sale plan | 27,400 | $13.00 | $356K | Form 4 |
| Sep 11, 2026 | Dawn Christine Maroney | President | Sale | 122,707 | $12.68 | $1.6M | Form 4 |
| Sep 11, 2026 | John E Kao | CEO | Sale plan | 385,270 | $12.68 | $4.9M | Form 4 |
| Sep 10, 2026 | John E Kao | CEO | Sale plan | 172,600 | $12.96 | $2.2M | Form 4 |
| Aug 14, 2026 | Dawn Christine Maroney | President | Sale plan | 5,000 | $14.00 | $70K | Form 4 |
| Aug 10, 2026 | John E Kao | CEO | Sale plan | 298,000 | $13.88 | $4.1M | Form 4 |
| Jul 15, 2026 | Dawn Christine Maroney | President | Sale plan | 177,068 | $20.83 | $3.7M | Form 4 |
| Jul 10, 2026 | John E Kao | CEO | Sale plan | 279,644 | $19.81 | $5.5M | Form 4 |
| Jul 10, 2026 | John E Kao | CEO | Sale plan | 18,356 | $20.65 | $379K | Form 4 |
| Jul 1, 2026 | Joseph S Konowiecki | Vice president | Sale plan | 25,000 | $24.00 | $600K | Form 4 |
| Jun 26, 2026 | Joseph S Konowiecki | Vice president | Sale plan | 25,000 | $23.00 | $575K | Form 4 |
| Jun 18, 2026 | Joseph S Konowiecki | Vice president | Sale plan | 25,000 | $22.00 | $550K | Form 4 |
| Jun 15, 2026 | Dawn Christine Maroney | President | Sale plan | 30,000 | $19.55 | $586K | Form 4 |
| Jun 12, 2026 | Hyong Kim | Chief Medical Officer | Sale plan | 35,951 | $19.86 | $714K | Form 4 |
| Jun 11, 2026 | Joseph S Konowiecki | Vice president | Sale plan | 25,000 | $21.00 | $525K | Form 4 |
| Jun 10, 2026 | John E Kao | CEO | Sale plan | 74,936 | $19.65 | $1.5M | Form 4 |
| Jun 10, 2026 | John E Kao | CEO | Sale plan | 223,064 | $20.60 | $4.6M | Form 4 |
| Jun 2, 2026 | Mark D. Kent | President | Purchase | 14,848 | $13.31 | $198K | Form 4 |
| May 15, 2026 | Dawn Christine Maroney | President | Sale plan | 30,000 | $16.09 | $483K | Form 4 |
| May 11, 2026 | John E Kao | CEO | Sale plan | 280,893 | $16.85 | $4.7M | Form 4 |
| May 11, 2026 | John E Kao | CEO | Sale plan | 17,107 | $17.54 | $300K | Form 4 |
| Apr 15, 2026 | Dawn Christine Maroney | President | Sale plan | 30,000 | $20.87 | $626K | Form 4 |
| Apr 13, 2026 | John E Kao | CEO | Sale plan | 82,299 | $20.80 | $1.7M | Form 4 |
| Apr 10, 2026 | John E Kao | CEO | Sale plan | 201,900 | $20.58 | $4.2M | Form 4 |
| Apr 10, 2026 | John E Kao | CEO | Sale plan | 13,801 | $21.38 | $295K | Form 4 |
| Apr 7, 2026 | James M Head | CFO | Sale | 11,100 | $21.08 | $234K | Form 4 |
| Apr 7, 2026 | John E Kao | CEO | Sale plan | 117,759 | $21.40 | $2.5M | Form 4 |
| Apr 7, 2026 | John E Kao | CEO | Sale plan | 132,241 | $20.67 | $2.7M | Form 4 |
| Apr 1, 2026 | Christopher J Joyce | Chief Legal and Admin. O | Sale plan | 18,013 | $17.79 | $320K | Form 4 |
| Mar 23, 2026 | John E Kao | CEO | Sale plan | 118,000 | $17.48 | $2.1M | Form 4 |
| Mar 19, 2026 | Andreas P. Wagner | Chief Human Resources Of | Sale plan | 11,602 | $18.22 | $211K | Form 4 |
| Mar 18, 2026 | Sebastian Burzacchi | COO - Mgmt Services Org | Sale | 15,361 | $17.84 | $274K | Form 4 |
| Mar 18, 2026 | Hyong Kim | Chief Medical Officer | Sale | 18,404 | $17.84 | $328K | Form 4 |
| Mar 18, 2026 | Christopher J Joyce | Chief Legal and Admin. O | Sale | 25,125 | $17.84 | $448K | Form 4 |
| Mar 18, 2026 | Dawn Christine Maroney | President | Sale | 36,749 | $17.84 | $656K | Form 4 |
| Mar 18, 2026 | John E Kao | CEO | Sale | 73,046 | $17.84 | $1.3M | Form 4 |
| Mar 18, 2026 | Robert L. Scavo | Chief Information Office | Sale | 11,285 | $17.84 | $201K | Form 4 |
| Mar 18, 2026 | Andreas P. Wagner | Chief Human Resources Of | Sale plan | 12,000 | $17.84 | $214K | Form 4 |
| Mar 16, 2026 | Dawn Christine Maroney | President | Sale plan | 30,000 | $17.48 | $524K | Form 4 |
| Mar 12, 2026 | Robert L. Scavo | Chief Information Office | Sale | 3,799 | $17.48 | $66.4K | Form 4 |
| Mar 12, 2026 | Robert L. Scavo | Chief Information Office | Sale | 245 | $16.99 | $4.2K | Form 4 |
| Mar 12, 2026 | Dawn Christine Maroney | President | Sale | 1,763 | $16.99 | $30K | Form 4 |
| Mar 12, 2026 | Dawn Christine Maroney | President | Sale | 27,350 | $17.48 | $478K | Form 4 |
| Mar 12, 2026 | John E Kao | CEO | Sale | 45,938 | $17.48 | $803K | Form 4 |
| Mar 12, 2026 | John E Kao | CEO | Sale | 2,961 | $16.99 | $50.3K | Form 4 |
| Mar 10, 2026 | John E Kao | CEO | Sale plan | 180,000 | $18.19 | $3.3M | Form 4 |
| Mar 4, 2026 | Andreas P. Wagner | Chief Human Resources Of | Sale plan | 21,118 | $18.62 | $393K | Form 4 |
| Feb 17, 2026 | Dawn Christine Maroney | President | Sale plan | 30,000 | $20.63 | $619K | Form 4 |
| Feb 10, 2026 | Andreas P. Wagner | Chief Human Resources Of | Sale | 22,238 | $20.47 | $455K | Form 4 |
| Feb 10, 2026 | John E Kao | CEO | Sale plan | 180,000 | $20.49 | $3.7M | Form 4 |
| Jan 15, 2026 | Dawn Christine Maroney | President | Sale plan | 14,871 | $22.78 | $339K | Form 4 |
| Jan 15, 2026 | Dawn Christine Maroney | President | Sale plan | 15,129 | $22.19 | $336K | Form 4 |
| Jan 12, 2026 | John E Kao | CEO | Sale plan | 177,273 | $21.10 | $3.7M | Form 4 |
| Jan 12, 2026 | John E Kao | CEO | Sale plan | 2,727 | $21.57 | $58.8K | Form 4 |
| Jan 6, 2026 | Hyong Kim | Chief Medical Officer | Sale plan | 16,506 | $21.35 | $352K | Form 4 |
| Jan 6, 2026 | Dawn Christine Maroney | President | Sale plan | 228,152 | $21.33 | $4.9M | Form 4 |
| Jan 2, 2026 | Christopher J Joyce | Chief Legal and Admin. O | Sale plan | 10,611 | $20.03 | $213K | Form 4 |
| Jan 2, 2026 | Dawn Christine Maroney | President | Sale plan | 100,000 | $20.03 | $2M | Form 4 |
| Dec 29, 2025 | Robert L. Scavo | Chief Information Office | Sale | 3,813 | $19.38 | $73.9K | Form 4 |
| Dec 29, 2025 | Robert L. Scavo | Chief Information Office | Sale | 65,728 | $18.71 | $1.2M | Form 4 |
| Dec 29, 2025 | Hyong Kim | Chief Medical Officer | Sale | 696 | $19.38 | $13.5K | Form 4 |
| Dec 29, 2025 | Hyong Kim | Chief Medical Officer | Sale | 11,998 | $18.71 | $224K | Form 4 |
| Dec 29, 2025 | John E Kao | CEO | Sale | 33,211 | $19.38 | $644K | Form 4 |
| Dec 29, 2025 | John E Kao | CEO | Sale | 572,437 | $18.71 | $10.7M | Form 4 |
| Dec 29, 2025 | Dawn Christine Maroney | President | Sale | 266,603 | $18.71 | $5M | Form 4 |
| Dec 29, 2025 | Dawn Christine Maroney | President | Sale | 15,467 | $19.38 | $300K | Form 4 |
| Dec 29, 2025 | Christopher J Joyce | Chief Legal and Admin. O | Sale | 15,299 | $18.71 | $286K | Form 4 |
| Dec 29, 2025 | Christopher J Joyce | Chief Legal and Admin. O | Sale | 888 | $19.38 | $17.2K | Form 4 |
| Dec 15, 2025 | Dawn Christine Maroney | President | Sale plan | 113,319 | $20.01 | $2.3M | Form 4 |
| Dec 12, 2025 | Dawn Christine Maroney | President | Sale plan | 16,681 | $20.02 | $334K | Form 4 |
| Dec 12, 2025 | General Atlantic (ALN HLTH), L.P. | 10% owner | Sale | 11.12M | $18.57 | $206M | Form 4 |
| Dec 10, 2025 | Sebastian Burzacchi | COO - Mgmt Services Org | Sale | 12,585 | $19.26 | $242K | Form 4 |
| Dec 10, 2025 | John E Kao | CEO | Sale plan | 180,000 | $19.02 | $3.4M | Form 4 |
| Dec 8, 2025 | Christopher J Joyce | Chief Legal and Admin. O | Sale plan | 19,706 | $19.33 | $381K | Form 4 |
| Nov 25, 2025 | Joseph S Konowiecki | Director | Sale plan | 25,000 | $19.00 | $475K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| General Atlantic (ALN HLTH), L.P. | 10% owner | – | $206M | Dec 12, 2025 |
| John E Kao | Chief Executive Officer, Director | – | $69.8M | Sep 14, 2026 |
| Dawn Christine Maroney | President | – | $24.7M | Sep 11, 2026 |
| Joseph S Konowiecki | Director | – | $3M | Nov 10, 2026 |
| Hyong Kim | Chief Medical Officer | – | $1.9M | Oct 6, 2026 |
| Christopher J Joyce | Chief Legal and Admin. Officer | – | $1.7M | Apr 1, 2026 |
| Robert L. Scavo | Chief Information Officer | – | $1.6M | Mar 18, 2026 |
| Andreas P. Wagner | Chief Human Resources Officer | – | $1.3M | Mar 19, 2026 |
| Sebastian Burzacchi | COO - Mgmt Services Org | – | $516K | Mar 18, 2026 |
| James M Head | Chief Financial Officer | – | $234K | Apr 7, 2026 |
| Mark D. Kent | President - MSO | $198K | – | Jun 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ALHC short interest
High short interest. 11.1% of ALHC shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 8%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 23.15M ALHC shares were sold short, 11.1% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 5.93M shares, buying them all back would take about 3.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 23.15M | 11.06% | -9% | 5.93M | 3.9 |
| Oct 15, 2026 | 25.52M | 12.30% | +8% | 11.33M | 2.2 |
| Sep 30, 2026 | 23.61M | 11.38% | -4% | 14.64M | 1.6 |
| Sep 15, 2026 | 24.62M | 11.87% | +8% | 6.96M | 3.5 |
| Aug 31, 2026 | 22.84M | 11.01% | -3% | 3.78M | 6.0 |
| Aug 14, 2026 | 23.53M | 11.35% | +7% | 6.54M | 3.6 |
| Jul 31, 2026 | 22.05M | 10.63% | -11% | 4.78M | 4.6 |
| Jul 15, 2026 | 24.81M | 12.00% | +2% | 5.32M | 4.7 |
| Jun 30, 2026 | 24.37M | 11.79% | -4% | 5.14M | 4.7 |
| Jun 15, 2026 | 25.42M | 12.30% | -0% | 8.13M | 3.1 |
| May 29, 2026 | 25.44M | 12.30% | +1% | 3.46M | 7.4 |
| May 15, 2026 | 25.08M | 12.13% | +56% | 9.24M | 2.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Alignment Healthcare company events
Alignment Healthcare filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 29, 2026.
- Oct 29, 2026ResultsReleased financial results. Filing
- Oct 8, 2026AnnouncementShared information with investors. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- May 12, 2026RulesChanged its bylaws or articles. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 4, 2026AgreementAlignment Healthcare, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and the selling stockholder listed on Schedule II thereto with respect to an underwritten offering by the Selling Stockholder of 13,167,733 shares of the Company’s common stock, par value $0.001 per… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Alignment Healthcare financials
Famous investors that hold ALHC
5 of the 50 well-known investors we track reported holding ALHC in their latest 13F filing. The largest position is Israel Englander's, worth $36.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 4.48M | $36.5M | 0.0% | +206% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 3.14M | $25.6M | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.99M | $16.2M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 822,529 | $6.7M | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 667,900 | $5.5M | 0.0% | -33% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ALHC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 1.6% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 1.6% |
| Nov 5, 2026 | FMR LLC | 13G/A | 4.3% |
| Nov 5, 2026 | FMR LLC | 13G/A | 4.3% |
| Oct 5, 2026 | BlackRock, Inc. | 13G/A | 11.3% |
| Oct 5, 2026 | BlackRock, Inc. | 13G/A | 11.3% |
Questions about Alignment Healthcare, Inc. (ALHC) stock
Who owns the most ALHC stock?
The largest reported owner of Alignment Healthcare, Inc. (ALHC) is Picton Mahoney Asset Management, with 5.8% of the company. In total, 2 funds and institutions reported holding ALHC at the end of Q2 2026, together about 6% of the shares. See the largest owners.
Are ALHC insiders buying or selling?
In the last 12 months, ALHC insiders reported 1 open-market purchase worth $198K and 77 sales worth $311M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in ALHC?
As of Oct 30, 2026, 23.15M ALHC shares were sold short, 11.1% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 5.93M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.
Which famous investors hold ALHC?
5 of the 50 well-known investors we track reported ALHC in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $36.5M. See all holders.
Executive pay
Alignment Healthcare's chief executive was paid a total of $11.3M for the year ended Dec 31, 2025, up 77% from $6.4M the year before. In the last 12 months, Alignment Healthcare's executives and directors bought $198K of stock on the open market and sold $105M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.